


# LTL-310FR datasheet

<b>Origin</b>	Human prostate cancer	<b>Histopathology</b>	Castration-resistant prostate adenocarcinoma
<b>Year of establishment</b>	2014	<b>Doubling time</b>	27.33±3.28 days
<b>Local invasion</b>	Yes	<b>Metastasis</b>	Not determined
<b>Hormone Sensitivity</b>	Androgen -independent		

The LTL-310FR tumor tissue line (Fig. 1) is a castration-resistant subline of [LTL-310F](#); it was developed by castration (androgen ablation) of mice bearing LTL-310F xenografts. The LTL-310FR presents androgen-independent growth *in vivo*. Viable tissues of the LTL-310FR in early generations have been preserved by cryopreservation (DMSO), and can be readily resurrected for grafting.



## **Applications**

1. Preclinical evaluation of established and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis), tissue invasion, metastasis (in combination with metastatic lines) and angiogenesis.
2. Discovery of potential therapeutic targets and/or biomarkers for drug sensitivity.
3. Study of genetic and cellular mechanisms underlying castration resistance, chemoresistance, tumor growth, progression or metastasis (in combination with metastatic lines).

**For more information, please contact us by email: [LTL@bccrc.ca](mailto:LTL@bccrc.ca) or phone: (604) 675 8013**